Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6OC2

CSP1-cyc(Orn6D10)

6OC2 の概要
エントリーDOI10.2210/pdb6oc2/pdb
NMR情報BMRB: 30594
分子名称Competence-stimulating peptide type 1 (1 entity in total)
機能のキーワードmodulator for pneumococcal quorum sensing, synthetic cyclic peptide, biosynthetic protein
由来する生物種Streptococcus pneumoniae
タンパク質・核酸の鎖数1
化学式量合計2232.72
構造登録者
Yang, Y. (登録日: 2019-03-21, 公開日: 2020-01-08, 最終更新日: 2023-06-14)
主引用文献Yang, Y.,Lin, J.,Harrington, A.,Cornilescu, G.,Lau, G.W.,Tal-Gan, Y.
Designing cyclic competence-stimulating peptide (CSP) analogs with pan-group quorum-sensing inhibition activity inStreptococcus pneumoniae.
Proc.Natl.Acad.Sci.USA, 117:1689-1699, 2020
Cited by
PubMed Abstract: is an opportunistic human pathogen that utilizes the competence regulon, a quorum-sensing circuitry, to acquire antibiotic resistance genes and initiate its attack on the human host. Interception of the competence regulon can therefore be utilized to study cell-cell communication and behavioral changes, as well as attenuate infectivity. Herein we report the design and synthesis of cyclic dominant negative competence-stimulating peptide (dnCSP) analogs capable of intercepting the competence regulon in both specificity groups with activities at the low nanomolar range. Structural analysis of lead analogs provided important insights as to the molecular mechanism that drives CSP receptor binding and revealed that the pan-group cyclic CSPs exhibit a chimeric hydrophobic patch conformation that resembles the hydrophobic patches required for both ComD1 and ComD2 binding. Moreover, the lead cyclic dnCSP, CSP1-E1A-cyc(Dap6E10), was found to possess superior pharmacological properties, including improved resistance to enzymatic degradation, while remaining nontoxic. Lastly, CSP1-E1A-cyc(Dap6E10) was capable of attenuating mouse mortality during acute pneumonia caused by both group 1 and group 2 strains. This cyclic pan-group dnCSP is therefore a promising drug lead scaffold against infections that could be administered individually or utilized in combination therapy to augment the effects of current antimicrobial agents.
PubMed: 31915298
DOI: 10.1073/pnas.1915812117
主引用文献が同じPDBエントリー
実験手法
SOLUTION NMR
構造検証レポート
Validation report summary of 6oc2
検証レポート(詳細版)ダウンロードをダウンロード

248335

件を2026-01-28に公開中

PDB statisticsPDBj update infoContact PDBjnumon